% of patients with RNA-HCV undetectable [ Time Frame: 24 weeks after end of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

% of patients with RNA-HCV undetectable at different moments of the treatment according genotype, viremia, liver fibrosis, number of CD4 cells and previous therapy [ Time Frame: At weeks 4, 12, 24 and 48 on treatment ] [ Designated as safety issue: No ]

History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease

Hepatocarcinoma observed in the liver ecography.

History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease

History or other evidence of chronic pulmonary disease associated with functional limitation

Drug use within 6 months of 1st dose and excessive alcohol consumption.

Concomitant treatment with ddI

Male partners of women who are pregnant

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00530972